Item type |
学術雑誌論文 / Journal Article(1) |
公開日 |
2014-06-12 |
タイトル |
|
|
タイトル |
Prospective Study of Gefitinib Readministration After Chemotherapy in Patients With Advanced Non-Small-Cell Lung Cancer Who Previously Responded to Gefitinib |
言語 |
|
|
言語 |
eng |
DOI |
|
|
|
関連識別子 |
https://doi.org/10.1016/j.cllc.2012.01.006 |
|
|
関連名称 |
10.1016/j.cllc.2012.01.006 |
キーワード |
|
|
主題 |
Chemotherapy, EGFR mutation, Epidermal growth factor receptor tyrosine kinase inhibitor, Gefitinib responder, Non-small-cell lung cancer, Recharrenge |
資源タイプ |
|
|
資源 |
http://purl.org/coar/resource_type/c_6501 |
|
タイプ |
journal article |
著者 |
Koizumi, Tomonobu
Agatsuma, Toshihiko
Ikegami, Kayoko
Suzuki, Toshiro
Kobayashi, Takashi
Kanda, Shintaro
Yoshikawa, Sumiko
Kubo, Keishi
Shiina, Takayuki
Takasuna, Keiichirou
Matsuo, Akemi
Hayasaka, Muneharu
Morikawa, Miwa
Ameshima, Shingo
|
信州大学研究者総覧へのリンク |
|
|
氏名 |
Koizumi, Tomonobu |
|
URL |
http://soar-rd.shinshu-u.ac.jp/profile/ja.WakmHhkh.html |
出版者 |
|
|
出版者 |
CIG MEDIA GROUP, LP |
引用 |
|
|
内容記述 |
CLINICAL LUNG CANCER. 13(6):458-463 (2012) |
書誌情報 |
CLINICAL LUNG CANCER
巻 13,
号 6,
p. 458-463,
発行日 2012-11
|
抄録 |
|
|
内容記述 |
The present study was designed to prospectively evaluate the clinical efficacy of gefitinib readministration in patients with advanced non-small cell lung cancer who responded well to initial gefitinib, followed by cytotoxic chemotherapy. Twenty subjects were enrolled, and 3 and 6 patients achieved partial response and stable disease, respectively. These findings provide valuable information for the management of previous gefitinib responders. Introduction: Salvage treatment for acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitor in patients with non-small-cell lung cancer is a matter of clinical concern. Several retrospective reports have indicated the usefulness of epidermal growth factor receptor tyrosine kinase inhibitor readministration; however, there have been few prospective studies. Materials and Methods: This study was designed to prospectively evaluate the clinical efficacy of gefitinib readministration in patients with advanced or metastatic non-small-cell lung cancer who responded well to initial gefitinib treatment. The subjects received at least 1 regimen of cytotoxic chemotherapy after progressive disease with the initial gefitinib therapy. Gefitinib administration (250 mg/d, orally) was started after progressive disease with the previous chemotherapeutic regimen. The primary endpoint in the present study was the response rate. Results: Twenty patients were enrolled between April 2007 and May 2011. Three patients achieved partial response, and 6 showed stable disease. Thus, the overall response rate and disease control rate of gefitinib readministration were 15% (95% Cl, 3.21-37.9) and 45% (95% Cl, 23.1-68.5), respectively. Median progression-free survival and overall survival from the start of gefitinib readministration were 2.0 months (95% Cl, 0.9-3.1 months) and 12.0 months (95% Cl, 8.0-16.0 months), respectively. Conclusion: These results suggest that gefitinib readministration may be an option, albeit with a low response rate and short progression-free survival, for patients who responded well to initial gefitinib followed by systemic chemotherapy. These findings provide valuable information for the management of previous gefitinib responders. |
資源タイプ(コンテンツの種類) |
|
|
内容記述 |
Article |
ISSN |
|
|
収録物識別子タイプ |
PISSN |
|
収録物識別子 |
1525-7304 |
書誌レコードID |
|
|
収録物識別子タイプ |
NCID |
|
収録物識別子 |
AA11973261 |
PubMed |
|
|
|
関連識別子 |
https://pubmed.ncbi.nlm.nih.gov/22402083 |
|
|
関連名称 |
22402083 |
権利 |
|
|
権利情報 |
Copyright© 2012 Elsevier |
出版タイプ |
|
|
出版タイプ |
AM |
|
出版タイプResource |
http://purl.org/coar/version/c_ab4af688f83e57aa |
WoS |
|
|
URL |
http://gateway.isiknowledge.com/gateway/Gateway.cgi?&GWVersion=2&SrcAuth=ShinshuUniv&SrcApp=ShinshuUniv&DestLinkType=FullRecord&DestApp=WOS&KeyUT=000310411400008 |